(DXS3) Xtrackers - SP500 Inverse - Ratings and Ratios
Inverse Equity Returns, Daily Swap Contracts, Leveraged Exposure
Description: DXS3 Xtrackers - SP500 Inverse
The Xtrackers - S&P500 Inverse Daily Swap UCITS ETF (DXS3) is an exchange-traded fund designed to provide inverse daily exposure to the S&P 500 Index, allowing investors to potentially profit from a decline in the US stock market. As a leveraged/inverse equity ETF, it is geared towards sophisticated investors who can monitor and adjust their positions frequently.
Analyzing the ETFs characteristics, we observe that it is listed on the XETRA exchange and has its origins in Germany. The fund is managed by DWS, a well-established asset management company, as indicated by the provided URL (http://www.dws.lu). Given its structure as a UCITS ETF, it adheres to the Undertakings for the Collective Investment in Transferable Securities directive, implying a certain level of regulatory compliance and investor protection.
From a technical standpoint, while avoiding the repetition of specific technical data, its clear that DXS3 has been trending downwards, as indicated by its short-term and long-term moving averages. The Average True Range (ATR) suggests a moderate level of volatility, which is expected given its inverse and leveraged nature. To forecast its future price movement, we need to consider both the technical indicators and fundamental data. If we analyze the
Combining these insights, a potential forecast could be that DXS3 may continue to experience downward pressure if the S&P 500 Index rallies. However, if the S&P 500 were to decline, DXS3 could potentially rise, given its inverse nature. The current AUM of 121.80M EUR indicates a reasonable level of liquidity, which is a positive factor. Nonetheless, the ATR suggests that investors should be prepared for potential volatility. Therefore, a prudent strategy could involve closely monitoring the S&P 500s movements and adjusting DXS3 positions accordingly to manage risk.
To make an actionable decision, investors should weigh the potential benefits of inverse exposure against the risks associated with leveraged ETFs, including the potential for significant losses if the market moves in the opposite direction of the ETFs strategy. Its also crucial to consider the overall market conditions, the S&P 500s trend, and the ETFs expense structure before making an investment.
Additional Sources for DXS3 ETF
DXS3 ETF Overview
Market Cap in USD | 143m |
Category | Trading - Leveraged/Inverse Equity |
TER | 0.50% |
IPO / Inception | 2008-01-15 |
DXS3 ETF Ratings
Growth Rating | -54.1 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -23.2 |
Analysts | - |
Fair Price Momentum | 4.68 EUR |
Fair Price DCF | - |
DXS3 Dividends
Currently no dividends paidDXS3 Growth Ratios
Growth Correlation 3m | -98% |
Growth Correlation 12m | -25.2% |
Growth Correlation 5y | -65.6% |
CAGR 5y | -11.46% |
CAGR/Max DD 5y | -0.24 |
Sharpe Ratio 12m | -1.07 |
Alpha | -8.65 |
Beta | -0.854 |
Volatility | 12.83% |
Current Volume | 406.6k |
Average Volume 20d | 193.4k |
Stop Loss | 5.3 (-2.8%) |
As of July 12, 2025, the stock is trading at EUR 5.45 with a total of 406,614 shares traded.
Over the past week, the price has changed by +1.02%, over one month by -5.76%, over three months by -18.51% and over the past year by -13.33%.
No, based on ValueRay´s Analyses, Xtrackers - SP500 Inverse (XETRA:DXS3) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -54.13 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DXS3 is around 4.68 EUR . This means that DXS3 is currently overvalued and has a potential downside of -14.13%.
Xtrackers - SP500 Inverse has no consensus analysts rating.
According to our own proprietary Forecast Model, DXS3 Xtrackers - SP500 Inverse will be worth about 5.1 in July 2026. The stock is currently trading at 5.45. This means that the stock has a potential downside of -7.16%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 5.1 | -7.2% |